Capricor Stock Jumps About 70% as Investors Reprice FDA Path for Deramiocel

Capricor Therapeutics shares surged about 70% in Friday morning trading as investors sharply repriced the regulatory outlook for deramiocel, the biotechnology company’s experimental treatment for Duchenne muscular dystrophy. Reuters reported the stock at $7.16 during its morning snapshot on August 14, still well below the $19.70 level seen before a series of FDA setbacks in late July.

The rally followed comments from Capricor Chief Executive Linda Marbán late Thursday that the Food and Drug Administration is willing to review additional information the company plans to submit. The regulatory disclosure came after Thursday’s market close, making Friday’s trading session the first regular-session market reaction.

The move was unusually large even for a small biotechnology company whose valuation depends heavily on one regulatory decision. In Reuters’ August 14 market report, analysts described the FDA’s willingness to consider the additional material as a potentially constructive signal, though the agency has not approved deramiocel and the ultimate outcome remains uncertain.

Capricor plans a new amendment focused on upper limb function

Marbán said Capricor intends to amend its biologics license application with 24-month data focused on upper limb function from the HOPE-3 program. She also said the FDA had indicated it was willing to review the new information and would push back the current decision deadline after receiving the submission. The existing Prescription Drug User Fee Act target action date is August 22.

The distinction matters because the July 29 FDA advisory committee vote addressed whether the evidence supported deramiocel for cardiomyopathy in patients with Duchenne muscular dystrophy. The panel voted 3 in favor and 9 against on that question. Capricor has emphasized that the committee was not asked to vote on the HOPE-3 study’s primary endpoint of upper limb function or on the therapy’s overall benefit-risk profile.

The FDA’s own meeting notice confirms that the committee was convened to discuss Capricor’s application for deramiocel for cardiomyopathy in Duchenne muscular dystrophy. The committee’s recommendation is advisory rather than binding, but it had become a major part of the market’s assessment of the drug’s approval prospects.

Capricor’s August 13 corporate update said HOPE-3 was designed and powered around upper limb function, with cardiac function as a key secondary endpoint. The company reported that the primary endpoint showed a statistically significant slowing of upper limb disease progression on the PUL 2.0 measure. It also acknowledged a change to the reported cardiac analysis after identifying an issue with the statistical model used in the clinical study report. The company said that change did not affect the HOPE-3 primary endpoint.

Reuters reported that the FDA’s willingness to consider the new package could lead to an extension of the review timeline. Roth Capital analysts said the submission may be treated as a major amendment, which they estimated could extend the process by about three months. That remains an analyst assessment, not an announced FDA timetable. The Department of Health and Human Services did not immediately comment to Reuters on the amended submission or a potential new deadline.

The 70% rally reverses only part of July’s collapse

Friday’s jump needs to be viewed against the losses that preceded it. FDA staff documents released on July 27 questioned the effectiveness evidence supporting deramiocel and criticized changes in how Capricor analyzed important trial outcomes. Reuters reported that the shares fell about 65% in early trading that day as investors reassessed the probability of approval.

Two days later, the advisory panel voted 9 to 3 against the effectiveness evidence for the cardiomyopathy indication. Capricor shares fell another 50% in morning trading on July 30, according to Reuters. The stock had traded at $19.70 before the late-July regulatory setbacks, compared with $7.16 in Reuters’ August 14 morning snapshot even after the roughly 70% rebound.

That price history helps explain why the new regulatory detail produced such a forceful reaction. The market was not pricing in an FDA approval on Friday. Rather, investors appeared to be assigning more value to the possibility that the application could remain under active consideration through an amended submission instead of moving directly toward rejection on the existing timetable.

Cantor analyst Kristen Kluska called the FDA’s willingness to review new muscle-function data a potentially positive surprise and reasoned that an extension would be difficult to square with an agency that had already made up its mind to reject the application. Oppenheimer analysts also interpreted the development as supportive of the upside case. Those views are analyst interpretations of the regulatory process, not statements from the FDA about the probability of approval.

The stock was also highly volatile after the initial surge, another sign that investors were trying to price a binary regulatory outcome rather than reacting to a conventional earnings beat or revenue update. A large percentage gain from a depressed base can still leave shareholders far below earlier levels, and Capricor’s August 14 trading fit that pattern.

Capricor has cash to wait, but deramiocel still dominates the investment case

Capricor’s latest financial position gives the company room to continue the regulatory process. In its second-quarter update, the company reported $237.9 million of cash, cash equivalents and marketable securities as of June 30, down from $318.1 million at the end of 2025. It posted a second-quarter net loss of about $40.7 million, or $0.70 per share, and said its current resources should fund operations for at least the next 12 months under its existing plan.

Management has already adjusted spending to reflect the regulatory uncertainty. Capricor said it is advancing commercial readiness at a slower pace pending greater clarity from the FDA. It also said programs not directly related to deramiocel, including its exosome-based platform, are on hold for now. That concentration means the FDA pathway for deramiocel has an outsized influence on the company’s near-term valuation.

The company has not received approval to market deramiocel in any indication. Its current strategy depends on whether the FDA accepts and how it evaluates the planned amendment, whether the review deadline is formally extended, and whether the agency considers the totality of the evidence sufficient for approval under a potentially narrower focus on upper limb function.

Friday’s roughly 70% rally shows how quickly those probabilities can be repriced in a development-stage biotech. It does not erase the July advisory-panel vote or the FDA staff’s earlier concerns. The next concrete regulatory milestone is the submission of Capricor’s amendment and the FDA’s response on the review timeline, which will determine whether the existing August 22 action date remains relevant.